Meeting
2024 ASCO Genitourinary Cancers Symposium
Mechanisms and strategies to overcome resistance to enfortumab vedotin in bladder cancer.
Authors
Kevin Chang
University of California, San Francisco, San Francisco, CA
Kevin Chang , Roshan Lodha , Henry M. Delavan , Jenna Winebaum , Sima P. Porten , Felix Y Feng , Carissa E Chu , Jonathan Chou
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Urothelial Carcinoma
Track
Urothelial Carcinoma
Sub Track
Translational Research, Tumor Biology, Biomarkers, and Pathology
Citation
J Clin Oncol 42, 2024 (suppl 4; abstr 690)
DOI
10.1200/JCO.2024.42.4_suppl.690
Abstract #
690
Poster Bd #
L12
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
Associations of TACSTD2/TROP2 and NECTIN-4/NECTIN-4 with molecular subtypes, PD-L1 expression and FGFR3 mutational status in two advanced urothelial bladder cancer cohorts.
First Author: Veronika Bahlinger
Poster
2022 ASCO Genitourinary Cancers Symposium
Sacituzumab govitecan (SG) plus enfortumab vedotin (EV) for metastatic urothelial carcinoma (UC) progressing on platinum-based chemotherapy and PD1/L1 inhibitors (ICB): Double antibody drug conjugate (DAD) phase I trial.
First Author: Bradley Alexander McGregor
Poster
2024 ASCO Annual Meeting
Clinical outcomes of sacituzumab govitecan (SG) after prior exposure to enfortumab vedotin (EV) in patients with metastatic urothelial carcinoma (mUC).
First Author: Michal Sternschuss
Poster
2024 ASCO Annual Meeting
Sacituzumab govitecan (SG) plus enfortumab vedotin (EV) for metastatic urothelial carcinoma (mUC) treatment-experienced (DAD) and with pembrolizumab (P) in treatment naïve UC (DAD-IO).
First Author: Bradley Alexander McGregor